ConductScience.org, home

Paper39765338

Efficacy of Combined Therapy With Silodosin and Solifenacin in Females With Overactive Bladder.

Jeon BJ and 5 others. Int Neurourol J, 2024. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Efficacy of Combined Therapy With Silodosin and Solifenacin in Females With Overactive Bladder. Papers, record 39765338. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39765338

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy of Combined Therapy With Silodosin and Solifenacin in Females With Overactive Bladder.
PubMed
Journal
Int Neurourol J
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
1.27, provisional
iCite
Revised in PubMed
2025-01-11
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jeon BJByeong Jo
2Chang HKHyun Kyung
3Tae BSBum Sik
4Park JYJae Young
5Yoon DKDuck Ki
6Bae JHJae Hyun

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT07822113A Multicenter Randomized Cross-Over Study Evaluating the Efficacy and Safety of Silodosin in Adult Women With Voiding DysfunctionBackground

Source ClinicalTrials.gov

Download CSV of trials

References18

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16823355Voiding difficulties in the female: prevalence, clinical and urodynamic review.Obstet Gynecol1983https://conductscience.org/library/papers/6823355PubMed
226663648A 12-Week, Open Label, Multi-Center Study to Evaluate the Clinical Efficacy and Safety of Silodosin on Voiding Dysfunction in Patients with Neurogenic Bladder.Low Urin Tract Symptoms2015https://conductscience.org/library/papers/26663648PubMed
328072862
Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis.
PLoS One2017https://conductscience.org/library/papers/28072862PubMed
419693954Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.Neurourol Urodyn2010https://conductscience.org/library/papers/19693954PubMed
534721668Effect of the symptom-based alpha-blocker treatment on lower urinary tract symptoms in women: systematic review and meta-analysis.Ther Adv Urol2021https://conductscience.org/library/papers/34721668PubMed
622983886Tamsulosin for voiding dysfunction in women.Int Urol Nephrol2012https://conductscience.org/library/papers/22983886PubMed
729609420Efficacy of an Alpha-Blocker for the Treatment of Nonneurogenic Voiding Dysfunction in Women: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial.Int Neurourol J2018https://conductscience.org/library/papers/29609420PubMed
819941278An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.Neurourol Urodyn2010https://conductscience.org/library/papers/19941278PubMed
921617983Efficacy and safety of combined therapy with tamsulosin and tolterodine in female patients with a maximal flow rate less than 12 ml/s.Int Urogynecol J2011https://conductscience.org/library/papers/21617983PubMed
1039140022Therapeutic effectiveness and adverse drug reactions of mirabegron versus solifenacin in the treatment of overactive bladder syndrome.Perspect Clin Res2024https://conductscience.org/library/papers/39140022PubMed
1124361007Antimuscarinics and α-blockers or α-blockers monotherapy on lower urinary tract symptoms--a meta-analysis.Urology2014https://conductscience.org/library/papers/24361007PubMed
1228954464Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder.Int Neurourol J2017https://conductscience.org/library/papers/28954464PubMed
1331327266Alpha-Blocker Use and the Risk of Hypotension and Hypotension-Related Clinical Events in Women of Advanced Age.Hypertension2019https://conductscience.org/library/papers/31327266PubMed
1421788967
Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
Prostate Cancer Prostatic Dis2011https://conductscience.org/library/papers/21788967PubMed
1516893438Solifenacin significantly improves all symptoms of overactive bladder syndrome.Int J Clin Pract2006https://conductscience.org/library/papers/16893438PubMed
1624615630α-adrenergic blockers for the treatment of lower-urinary-tract symptoms and dysfunction in women.Ann Pharmacother2014https://conductscience.org/library/papers/24615630PubMed
1719898824Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study.World J Urol2011https://conductscience.org/library/papers/19898824PubMed
1833567116Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction.Cochrane Database Syst Rev2021https://conductscience.org/library/papers/33567116PubMed

Download CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
40903563
Novel spectrophotometric approaches for analysis of solifenacin and silodosin in pharmaceutical preparations, human plasma, and environmental water samples: assessment of the methods' greenness and practicality.
Anal Bioanal Chem2025https://conductscience.org/library/papers/40903563PubMed
39765336Innovation and the Importance of Patient-Centered Treatment.Int Neurourol J2024https://conductscience.org/library/papers/39765336PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39765338

GET https://conductscience.org/api/papers/v1/39765338/authors